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Abstract
Gorlin-Goltz syndrome, also known as nevoid basal cell carcicoma syndrome, comes into being due to a genetic alte-
ration produced by a mutation in the “Patched” tumour suppressor gene, and it is inherited in a dominant autosomal 
way, though sporadic cases have been found. This syndrome shows a high penetrance and variable expressiveness. It 
is about a multisystemic process that is characterised by the presence of multiple pigmented basocellular carcinomas, 
keratocysts in the jaws, palmar and/or plantar pits and calcification of the falxcerebri. Together with these major fea-
tures a great number of processes considered as minor features have also been described. The latter include numerous 
skeletical, dermatology related and neurological anomalies among others. In some occasions, the presence of very 
aggressive basocellular carcinomas has been described as well as other malignant neoplasias. Due to the importance 
of oral maxillofacial manifestations of this syndrome, it is fundamental to know its characteristic in order to make 
a diagnosis, an early preventive treatment and establish right genetic advice. In this work the main clinicopathologic 
and the therapeutic aspects related to the syndrome under consideration have been revised and updated.
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Introduction
Gorlin-Goltz syndrome is an infrequent multisystemic 
disease that is inhereted in a dominant autosomal way, 
which shows a high level of  penetrance and variable 
expressiveness (1-7). This syndrome has received several 
names throughout the times such as "basal cell nevus 
syndrome" (8,9), "nevoid basal cell carcinomas syndrome" 
(1,2,4-7,10), or the most complex name of "multiple basal 
epithelioma, jaw cysts and bifid rib syndrome" (11).
In 1894 Jarisch and White (12,13) made the first descrip-
tions of patients with this syndrome, highlighting the pre-
sence of multiple basocellular carcinomas. Later, in 1939, 
Straith (14) described a familiar case in which multiple 
basocellular carcinomas and cysts appeared. In 1953 Gross 
(15) presented a case suggesting additional signs such as 
synostosis of the first left rib and bilateral bifurcation of 
the sixth ribs. On the other hand, Bettley (16) and Ward 
(17) were the first to relate the presence of palmar and 
plantar pits with the syndrome. Nevertheless, it was not 
until 1960 when Gorlin and Goltz (18) established a classi-
cal triad that characterises the diagnosis of this syndrome 
(multiple basocellular epitheliomas, keratocysts in the jaws 
and bifid ribs). This triad was later modified by Rayner 
et al. (19), who established that for giving the diagnosis at 
least cysts had to appear in combination with calcification 
of the falxcerebri or palmar and plantar pits. 
The Gorlin-Goltz syndrome presents a quite variable esti-
mated prevalence, which goes from 1 in 57.000 (5) to 1 in 
256.000 inhabitants (20). This frequency varies according 
to the country where the study has been carried out. For 
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instance, in a study in England (21) the frequency is of 
1 in 55.6000. In Italy, on the other hand (20), is of 1 in 
256.000 and in Australia a study showed a prevalence of 
1 in 164.000 (22). Nevertheless, it is generally accepted a 
prevalence of 1 in 60.000 inhabitants (2). 
This syndrome probably presents itself in all ethnic groups, 
although a few cases have been published in certain 
human races, and it affects both men and women in the 
same way.
During the lasts years very important advances have been 
taking place in the knowledge of the genetic characteristics 
of this syndrome, existent clinicopathologic variants and 
its different manifestations (8,10,23). This piece of work 
attempts to update the clinicopathologic knowledge of 
the syndrome under consideration.
Genetic aspects
Gorlin-Goltz syndrome is an autosomal dominant inhe-
rited disorder with high penetrance and variable fenotype 
expressiveness which can manifest itself  spontaneously 
(1-7,9,23,24). It is considered that between the 30% and 
50% of patients who suffer from this syndrome do not 
know if  any of their family members has had it.
The tumour suppressor gene called Patched (PTCH) , 
located in the 9q22.3 cromosome, has been identified as 
the cause of Gorlin-Goltz syndrome (2,5-7,23-25). This 
gene is composed of 23 exons and codifies a transmem-
brane glucoprotein composed of 1447 amino acids and 
12 domains (5,6,24,25). This protein can be found in the 
Hedgehog signalling pathway. This signalling cell route 
regulates a great variety of processes such as the embrio-
genesis, homeostasis mantainance in the old tissues, tissue 
repairing during the persistent cronic inflammation and 
carcinogenesis. (26-28).
When Hedgehog is absent, the family of  PTCH trans-
membrane receptors inhibit the protein that emits the 
Smoothened (SMO) signal. On the contrary, when Hed-
gehog combines PTCH, SMO signal is released, causing 
the activation of certain genes such as GLI1, PTCH 1, 
CCND2, FOXL1 and JAG (29, 30). 
Gorlin-Goltz syndrome is produced due to a mutation in 
this gene, with loss of heterozygosity (4-7,25). This loss has 
also been observed in basocellular carcinomas without any 
relation to the syndrome, in the meduloblastoma and in 
odontogenic keratocysts (6). Nearly 40% of the syndrome 
cases present as new mutations (4,6,7,25), and they do not 
seem to represent any polygenetic alteration (7).
Since the discovery of PTCH gene as being the responsible 
for the Gorlin-Goltz syndrome in 1996 (4), more than 60 
germinal mutations of PTCH have been identified and 
described. Several methods were used to study these muta-
tions in patients` families in the USA, Sweden, Australia, 
the United Kingdom, Japan, China and France (1,4,24). 
The mutations are related to a premature truncation of 
the PTCH gene protein and to some missense, frameshift 
and nonsense mutations, identified in the transmembrane 
domains (1,4,24). Nevertheless, missense mutations  do not 
occur with the same frequency as frameshift or nonsense 
mutations (24) 
Patients suffering from Gorlin-Goltz syndrome show 
an important variability in their phenotype- it has been 
observed that individuals with the same molecular altera-
tions present very different symptoms (31). The fact that 
there is no relationship between the genotype and the 
phenotypein this syndrome suggests the existence of a very 
complex variability of the phenotype (4). This variation is 
thought to be originated due to the interaction of genetic 
and environmental factors (2,24).
Clinicopathologic aspects
In order to make a diagnosis of the Gorlin-Goltz syndrome 
some diagnosis criteria have to be taken into account.
The most important criteria to make a diagnosis for this 
syndrome are the presence of  pigmented basocellular 
carcinomas, odontogenic keratocysts, palmar and/or 
plantar pits and ectopic calcifications of the falxcerebri 
(1-4,6,8-11,23-25).
Together with these major features more that 100 minor 
features have been described. The more relevant are the 
following: cardiac or ovarian fibroma, macroencephaly, 
bifid ribs, cyphoscoliosis, cleft palate, medulloblastoma 
(1-2 % is attributed to the syndrome and from 3 to 5 % 
is the incidence in this syndrome), alterations in the sella 
tucica, mandibular prognathia, lateral displacement of the 
inner canthus, frontal and biparietal bossing, imperfect 
segmentation of the cervical vertebrae, linfomesenteric 
cysts that tend to calcify, meningiomas, fibrosarcoma, 
rhabdomyosarcoma, short fourth metacarpal, strabism, 
ocular hypertelorism, congenital blindness, spina bifida 
occulta, pectum excavatum, high arched eyebrows and 
palate, narrow sloping shoulders, immobile thumbs, low-
pitch voice in women, renal anomalies and hypogonadism 
in men (2,3,8,10,11,23). In certain occasions, a tall height 
and even similar characteristics to acromegaly have been 
associated with the syndrome (23).
There are two options to make a correct diagnosis of 
the Gorlin-Goltz syndrome, or two major features and 
one minor feature (23). In table 1, the main alterations 
that have been described in relation to this syndrome are 
presented.
The odontogenic keratocysts represent from 3 to 15% 
out of  the total number of  odontogenic cysts (9) and 
they appear in the 65-75 % of the cases of the syndrome 
(1,10,11,23). These cysts represent a particular entity that 
has been of interest, mainly due to biological aggressi-
veness and to the great amount of recurrence (1,7-11). 
Recently and based on the intrinsic growth potential of 
its epithelial coating, they have been re-classified and ca-
lled odontogenic keratocyst tumours, and they have been 
included in the odontogenic neoplasias (7,11). Genetically, 
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SKELETAL ANOMALIES
Bridging sella turcica (60-80 %)                   Syndactyly and/or oligodactyly
Scoliosis (50%)                                                  Shortened 4th metacarpal
Bifid rib (40%) Splayed/fused ribs
Occult bifid rib (cervical, thoracic or both 
of which 40%)
Cervical ribs
Absent ribs (26%) Sprengel scapular deformity
Hemivertebrae Pectum excavatum, carinatum
Flatfoot Pelvic calcification
Polydactyly
Another: arachnodactyly, hallux valgus, 
cortical defects in long bones.
SKIN ANOMALIES
Basal cell carcinoma (50-97%) Milia, specially in limbs
Palmar and/or plantar pits (60-90%) Comedones
CRANIOFACIAL ANOMALIES
Calcification of the cerebral falx (37-79%) Brachycephaly
Macrocephaly (40%) Tentorium cerebellum calcification
Frontal bossing (25%) Bridged in sella turcica
Coarse face Coroidal cysts (3º-4º ventricles)
SEXUAL ANOMALIES
Uterine and ovarian fibromas (15%) Supernumerary  nipple
Ovarian fibrosarcoma Hypogonadism and cryptorchidism
Calcified ovarian cysts
Female distribution of the pubis hair, 
scarce beard in men and ginecomastia.
NEUROLOGICAL ANOMALIES
Medulloblastoma (3-5%) Agenesis/ disgenesis of corpus callosum
Meningioma (1% or less) Schizophrenic personality
Mental retardation Nervous deafness 
Congenital hydrocephalus Anosmia
OPHTHALMIC ANOMALIES
Hypertelorism (40%) Glaucoma
Exotropia Choroidal and/or optic nerve coloboma
Congenital amaurosis Congenital blindness and opaque cornea
Ptosis Cataracts
Internal strabismus (15%) convergent /
divergent
Chalazion
OROFACIAL ANOMALIES
Odontogenic keratocysts (75%) Palate or maxillary sinus fibroma 
High–arched palate or prominent palatine 
ridges (40%)
Malocclusion (maxillary hypoplasia and 
mandibular hyperplasia, cleft palate)
Cleft lip and/or palate (4%) Fibrosarcoma of the jaws
Impacted teeth and/or agenesis. Dental 
ectopic position.
Ameloblastoma
ANOTHER: Inguinal hernia, renal anomalies, lymphomesenteric cysts, left ventricular 
fibroma (neonatal) and cardiac fibroma (3%).
Table 1. Anomalies described in Gorlin-Goltz Syndrome.
References (2,3,8,10,11,23)
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the loss of heterozygosity of the tumour suppression genes 
that can be found in these lesions, leads to conclude that 
the keratocysts have a neoplastic origin and that they are 
not just an anomaly of the cyst development (9). In spite 
of this discovery this is still a very controversial issue. 
These types of cysts manifest themselves for the first time 
during the first decade in life (8,10,11), and when they 
present in an isolated way, i.e. without any association with 
the syndrome, their major incidence is in the second and 
third decade in life (10,11). There are no sexual differences 
in isolated keratocysts but still there is a more frequent 
appearance among men (66%) that have the syndrome 
(11). The cysts can be found in any part of the maxillar 
if  they are associated with the syndrome whereas isolated 
keratocysts appear more frequently (65-83%) preferably 
in the body and upper part of the jaw. Radiographically, 
they appear in syndrome as multiple uni or multiocular 
lesions, of variable size with sclerotic borders, and they 
can be uni or bilateral (9-11, 23) (Figure 1).
Histologicallly speaking, the keratocysts have a well de-
fined scale-like parakeratinised stratified epithelium with 
an average thickness of 5 to 8 cells, with a basal layer in 
which cells present themselves fenced up in a corrugated 
surface and a connective wall rich in mucopolisacarids, 
without inflammatory infiltration and with a variable 
number of microcysts and epithelial islets (8-11) (Figure 
2). Its high potential of recurrence is justified by the high 
mitotic epithelial activity, the frequency of satellite cysts, 
pieces of epithelium and prolific dental sheet, and by the 
existence of a epithelial coating thicker than in other jaw 
cysts (7,10,11).
Basocellular carcinomas have different manifestations de-
pending on whether they are associated with the syndrome 
or not (Table 2). The more frequent skin lesions in the 
Gorlin-Goltz syndrome are the basocellular carcinomas 
(10). These tumours are much more frequent in the skin of 
white people (80%) than in people of black race (38%) (10). 
Epidemiologic studies have demonstrated that sunlight 
and particularly UV radiation are key risk factors for the 
basocellular carcinomas development. This explains the 
low frequency of these lesions in Afroamerican people 
due to the protection action of the melanin pigmentation 
(8,10). Experimentation with mice has demonstrated the 
development of these basocellular carcinomas when they 
were exposed to UV rays. This exposure produced muta-
tions in the PTCH gene (10), which would confirm that the 
basocellular carcinomas development in patients suffering 
from Gorlin- Goltz syndrome would be stimulated by UV 
rays irradiation (10). That is the reason why it is importat 
to protect patients` skin from sunshine, especially before 
clinical manifestations appear.
Basocellular carcinomas that are present in the Gorli-
Goltz syndrome vary from one to hundreds and they have 
a wide spectrum of clinical presentations that go from light 
to dark papulae of hard consistence and plane surface, to 
ulcerated pigmented plaques of different size (10). The 
carcinomas can clinically manifest themselves from puber-
ty to the mid-thirties and they more frequently affect the 
cutaneous surface of the thorax and the cervicofacial area 
(10,23). Periocular areas, eyelids, the nose, the malar region 
and the upper lip are the areas commonly affected. The 
basocellular carcinomas rarely produce any pain. Most of 
them are located in the epidermis although, throughout 
DATA
Basocellular carcinoma no-assoaciated to the 
Gorlin-Goltz Syndrome
Basocellular carcinoma associated to the Gorlin-
Goltz Syndrome
Number Only one  50 to 100
Sex More frequent in men Equally frequency in both of the sex
Location Half third facial 
Face, neck, back, thorax, abdomen and upper 
part of the body 
Clinical
characteristics
Papulae >> central ulceration
Variable colour
More frequent in white skins
Small papulaes, soft nodule or a  plane plaque.
Variable colour pink >> brown
Any colour of skin
Etiology Solar radiation Genetically determinated
Treatment
It depends on the size and the location
Surgery
Surgery
 Risk to develop new injuries
Table 2. Different manifestations of the basocellular carcinomas depending on whether they are associated to the Gorlin-Goltz  syndrome 
or not.
References: (8,10,11,23).
Fig. 1. Radiographic appearance of multiple radiolucent lesions in 
the jaw for odontogenic keratocysts.
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the years, they can invade the dermis. Generally, a local 
invasion takes place and the evidence of aggressiveness is 
often preceded by a size growth, ulceration, haemorrhage 
and scab formation (10). Histologically, the basocellular 
carcinomas do not show any difference whether they are 
associated with the syndrome or not, and they have the 
classical appearance of nets and chains of basophile cells 
orderly settled, with a great amount of melanin pigmen-
tation in many occasions (Figure 3).
Palmar and plantar pits are specific signs of this syndrome, 
and they appear as punctiform depressions in the palms 
and plants skin (8,23). These alterations are caused by 
the lack of a partial or complete absence of the corneal 
stratum. They are permanent, unpalpable and asyntoma-
tic, with a depth ranging from 2 to 3 mm. and a diameter 
that ranges from 1 to 3 mm.  (8,23). When the syndrome 
is present, they manifest in between the 50 and 70% of 
the patients and they usually get developed in the second 
decade of life, increasing in  the number with the age- they 
can increase to 500 (10).
More signs are currently being added to the list of compo-
nents of Gorlin-Goltz syndrome. For instance, Ramaglia 
et al. (23) showed that an eight-year-old girl was diagno-
sed with an incomplete fusion of Müller canals with a 
bicorneal uterous.
Diagnostic and therapeutic aspects
In the case of the Gorlin-Goltz syndrome it is of great 
importance to make an early diagnosis since severity in 
complications, such as skin and brain malignant tumours, 
can be reduced and so can the destruction and secondary 
oral maxillofacial deformities of the jaw cysts. An early 
diagnosis is important to give adequate genetic advice.
It is of major relevance to keep track of the family an-
tecedents clinical history and to examine the oral cavity, 
skin, thorax and cranium in an exhaustive way (3,11). An 
orthopantomography, a frontal-back thorax radiography 
and a craniofacial CT must be taken in order to detect 
osseous morphology aspects that cannot be seen in simple 
radiographies, and also a MR of the cranium and pelvic 
ultrasonographies in women. 
Patients suffering from the syndrome have to undergo 
check-ups at least once a year, especially the ones having 
odontogenic keratocysts (11).
The treatment of Gorlin-Goltz syndrome is the specific 
therapeutics of its clinical manifestations. In the case of 
odontogenic keratocysts, there are different treatment 
techniques to eliminate them and avoid the high rate of 
recurrence, which can reach up to a 62% of the cases (1,7-
10). The therapeutic techniques for the keratocysts vary 
from simple enucleation with curettage, to the enucleation 
with peripheral osteotomy or to osseous resection in block 
(1,10). This last technique is the most aggressive and it 
logically follows that the recurrence rate decreases (8). 
There are also more conservative options such as the local 
parietal therapy with Carnoy solution, with cryotherapy or 
marsupialisation of the cysts, or decompression followed by 
a secondary enucleation (9,10). Nevertheless, those methods 
are not efficient in the long term and their use is considered 
to be controversial (9,10). In order to decide which tech-
nique must be employed, the following factors have to be 
taken into account: lesion size, lesion extension, location, 
possible cortical and soft parts damage, the age and whether 
it is a primary or recurrent lesion (8). It is also important to 
detect if it is an isolated keratocyst or if it is associated with 
the syndrome, since in the last case the rate of recurrence is 
higher as Forsell et al. (11) have suggested- the recurrence 
rate is of 63% in keratocysts associated to the syndrome, 
and of 37% in the isolated ones (11).
As well as keratocysts, basocellular carcinomas treatment 
is also based on conventional surgical exeresis with or 
without reconstruction, or with other techniques such as 
CO2 laser (8,10). In primary small and well defined lesions 
without aggressive behaviour, curettage, electrodissection 
and cryosurgery techniques have also been used. However, 
these techniques have the problem of impeding the correct 
Fig. 2. Characteristic histopathologic aspect of keratinised 
epithelium of odontogenic keratocyst (H & E 60x).
Fig. 3. Histopathologic appearance of  basophile epithelial 
proliferation with melanin pigmentation in a basal cell carci-
noma (H & E  50x).
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histopathological estimate of the samples and, hence, the 
biological estimate and the possible extension to the surgical 
margins-very usual piece of data in this pathology.
In some plane superficial lesions which do not affect the 
hair follicle, photodynamic therapy with delta-amino-
levulinic acid has been employed, as well as the topical 
application of 5-fluorouracil to 0,1% (twice a day), or 
intralesional interferon alfa-2b or the chemotherapeutic 
paclitaxel agent, etc. (10). Local radiation therapy would 
not be advisable because of the tumour recurrence risk or 
because of the possible tumour growth (10).
As a conclusion, it can be said that Gorlin-Goltz syndrome 
is dominant autosomal genetic process- with the exception 
of sporadic mutation cases- which is of particular interest 
for the oral maxillofacial health experts. When a patient has 
this syndrome is of relevant importance to examine their 
family to detect possible clinical manifestations and in that 
way arrive at effective genetic advice. In order to be able 
to arrive at an early diagnosis of the syndrome, specialists 
should carry out a clinical radiographic testing in early 
ages of life. In this way, different health specialists play 
a key role: paediatricians, specialists in genetics, dentists, 
maxillofacial surgeons, dermatologists, etc. must have good 
basic knowledge of the main features of the syndrome to 
work accordingly in their different health specialities.
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